Latest Articles & Insights

Stay informed with the latest pharmaceutical regulations, industry insights, and expert guidance from our team of licensed pharmacists.

Podcast

March 21, 2026

Navigating the Mexican Regulatory Landscape: An Interview with R. Yoloxóchitl Macias Ortega of Anglex Consultores

R. Yoloxóchitl Macias Ortega discusses the intricacies of COFEPRIS, the digitalization of Mexican health registrations, and strategies for medical device manufacturers to enter the Latin American market efficiently.

Registration

March 20, 2026

Comparison of ElendiLabs and Arqon: Global Innovative Platform vs. Traditional In-Country Representation Expertise in Medical Device Regulatory Services

ElendiLabs stands out as a cheaper, more flexible global digital platform offering broader country coverage, free articles with verified consultants’ insights and case sharing, plus shorter response times through instant project matching; Arqon provides reliable traditional medical device consulting with in-country license holding, compliance support across EU, US and Asia (ASEAN), plus group services for training and business development. ElendiLabs delivers superior value, affordability, and scalability for worldwide regulatory success.

Registration

March 19, 2026

Comparison of ElendiLabs and Qualtechs: Global Innovative Platform vs. Asia-Focused Traditional Expertise in Medical Device and Pharmaceutical Regulatory Services

ElendiLabs stands out as a cheaper, more flexible global digital platform offering broader country coverage, free articles with verified consultants’ insights and case sharing, plus shorter response times through instant project matching; Qualtechs provides reliable one-stop traditional consulting and clinical trials with deep Asian expertise. ElendiLabs delivers superior value, affordability, and scalability for worldwide regulatory success.

Registration

March 19, 2026

Comparison of ElendiLabs and Pacific Bridge Medical: Global Innovative Platform vs. Asia-Focused Traditional Expertise in Medical Device and Pharmaceutical Regulatory Services

ElendiLabs stands out as a cheaper, more flexible global digital platform offering broader country coverage, free articles with verified consultants’ insights and case sharing, plus shorter response times through instant project matching; Pacific Bridge Medical provides reliable traditional regulatory and business development consulting with local agent representation, clinical trials, and exclusive Asia focus for medical devices, IVDs, pharmaceuticals, and biotech. ElendiLabs delivers superior value, affordability, and scalability for worldwide regulatory success.

Registration

March 18, 2026

Comparison of ElendiLabs and Asia Actual: Global Innovative Platform vs. Asia-Focused Traditional Expertise in Medical Device and IVD Regulatory Services

ElendiLabs stands out as a cheaper, more flexible global digital platform offering broader country coverage, free articles with verified consultants’ insights and case sharing, plus shorter response times through instant project matching; Asia Actual provides reliable local regulatory representation and market access in 16 APAC countries with experienced experts. ElendiLabs delivers superior value, affordability, and scalability for worldwide regulatory success.

Podcast

March 16, 2026

Navigating the EU MDR Marathon: An Interview with Andrew Gibson of AKRA TEAM

Host Teddy sits down with Andrew Gibson, Senior Managing Consultant at AKRA, to discuss the complexities, costs, timelines, and roadblocks of the European medical product regulatory landscape (EU MDR), with specific advice for startups.

Other

March 10, 2026

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products in Japan

PMDA's 2013 technical guidance facilitates simultaneous development and approval of in vitro companion diagnostics and corresponding therapeutic products for personalized medicine, covering biomarker patient identification, clinical trial design, validation timing, concordance studies, and analytical performance requirements to ensure efficacy and safety.

Other

March 10, 2026

Revised Points to Consider for Biomarker-Based Drug Approvals from Investigator-Initiated Trials in Rare Cancer Patients in Japan

PMDA revised its points to consider allowing partial change approval applications for biomarker-based drugs developed via investigator-initiated trials in rare cancer patients before companion diagnostics (CDx) approval, under conditions ensuring equivalent efficacy and safety via approved tests or alternatives, effective March 19, 2024.

Other

March 10, 2026

Handling of Drug-Agnostic Companion Diagnostics in Japan

Japan’s notification outlines procedures for designating drug-agnostic companion diagnostics (CDx) where multiple approved CDx can be used interchangeably to identify patients for various therapeutics, promoting personalized medicine and patient access.